Table 1. Baseline characteristics of study patients at PCI.
| Variables | Overall (n = 537) |
|---|---|
| Age, years | 69 [64–76] |
| Sex: male, n (%) | 392 (73) |
| Body mass index, kg/m2 | 23.8 [21.5–26.2] |
| Risk factors, n (%) | |
| Hypertension | 438 (82) |
| Diabetes mellitus | 313 (58) |
| Dyslipidemia | 408 (76) |
| Current smoker | 63 (12) |
| History of smoking | 81 (15) |
| Medication, n (%) | |
| Oral anticoagulation | 65 (12) |
| Calcium-channel blocker | 229 (43) |
| ACEI | 101 (19) |
| ARB | 225 (42) |
| β-blocker | 185 (34) |
| Ezetimibe | 40 (7) |
| Nitrates | 50 (9) |
| Proton pump inhibitor | 262 (49) |
| Laboratory data | |
| Hemoglobin, g/dL | 12.9±0.1 |
| hs-CRP, mg/L | 1.2 [0.4–3.2] |
| TC, mg/dL | 155 [136–181] |
| LDL-C (F) ≥ 70 mg/dL, n (%) | 348 (65) |
| LDL-C (M) ≥ 70 mg/dL, n (%) | 372 (69) |
| HDL-C ＜40 mg/dL, n (%) | 133 (25) |
| Non-HDL-C ≥ 100 mg/dL, n (%) | 304 (57) |
| TG ≥ 150 mg/dL, n (%) | 141 (26) |
| Uric acid, mg/dL | 5.9 [4.9–6.8] |
| FPG, mg/dL | 110 [96–133] |
| eGFR, mL/min/1.73 m2 | 61.4 [47.5–75.2] |
| LVEF, 50% | 58.3 [48.7–66.2] |
Values are shown as number and percentage or median with interquartile range. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; TC, Total cholesterol; TG, Triglyceride.